Startups
Immatics
Edit

Immatics

Trusted
http://www.immatics.com/
Last activity: 13.08.2026
Active
Categories: ActiveBioTechDevelopmentDrugGamingIndustryLegalTechMedtechTechnologyVideo
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.


QUICK FACTS

>250 Team members in Tuebingen and Munich, Germany and Houston, Texas
>200 Targets covering major solid tumors
- 2 proprietary technology platforms, XPRESIDENT® and XCEPTOR®
- 7 proprietary drug discovery programs; 3 of which are in clinical development
- Multiple partnered programs


Read more about Immatics on our homepage: https://immatics.com/


Find us also on Twitter:
Twitter: http://bit.ly/2DFbPre


Legal notice: https://immatics.com/imprint/
TwitterFacebookLinkedInEmail
Followers
1.34K
Followers
8.99K
Website visits
9.1K /mo.
Mentions
67

Overview

Location
Germany, Bavaria, Munich
Employees
201-500
Total raised
$446.39M
Founded date
2000

Investors 5

Funding Rounds 6

DateSeriesAmountInvestors
Sign up to seeSign up to seeSign up to seeSign up to see
Aug 28, 2019Funding round$75M
Oct 4, 2017Series E round$58M
Jul 16, 2014Series D round$45.99M
Oct 15, 2013Series D round$46.45M
Sep 21, 2010Series C round$70.95M

Mentions in press and media 67

DateTitleDescription
Sign up to seeSign up to seeSign up to see
Apr 26, 2025Granite Bio: A New Force in Immunology with $100 Million BackingGranite Bio has burst onto the scene, armed with $100 million in funding. This clinical-stage immunology company is not just another player; it’s a potential game-changer. With a focus on autoimmune diseases, Granite Bio is targeting the ro...
Apr 25, 2025Granite Bio: Immunology Company Debuts With $100 Million In FundingGranite Bio, a clinical-stage immunology company, announced it has emerged from stealth with $100 million in funding. This includes a $30 million Series A led by founding investors Versant Ventures and Novartis Venture Fund and a $70 millio...
Mar 27, 2025Immatics Announces Full Year 2024 Financial Results and Business UpdateRandomized-controlled Phase 3 trial, SUPRAME, to evaluate ACTengine® IMA203 TCR-T (PRAME) in advanced melanoma patients; first patient randomized and enrollment continues as planned ACTengine® IMA203 TCR-T (PRAME): Phase 1b IMA203 data publ...
Nov 18, 2024Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAMEThe Company will now target five major cancer types with its four clinically active compounds across both TCR-T cell therapies and TCR-based Bispecifics Today, Company discloses first clinical data from the TCR Bispecific molecule, TCER® IM...
Nov 18, 2024Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAMEThe Company will now target five major cancer types with its four clinically active compounds across both TCR-T cell therapies and TCR-based Bispecifics Today, Company discloses first clinical data from the TCR Bispecific molecule, TCER® IM...
Nov 8, 2024Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAMETwo oral presentations and multiple posters on clinical and preclinical-stage candidates to be presented at SITC, demonstrating the strength of Immatics’ TCR-T PRAME franchise to target solid cancers ACTengine® IMA203 demonstrates 54% cORR,...
Nov 8, 2024Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAMETwo oral presentations and multiple posters on clinical and preclinical-stage candidates to be presented at SITC, demonstrating the strength of Immatics’ TCR-T PRAME franchise to target solid cancers ACTengine® IMA203 demonstrates 54% cORR,...
Oct 11, 2024Immatics Secures $150 Million in Public Offering: A Bold Step in Cancer ImmunotherapyIn a significant move for the biopharmaceutical sector, Immatics N.V. has announced the pricing of a public offering that aims to raise $150 million. This offering, which involves 16,250,000 ordinary shares priced at $9.25 each, is a strate...
Oct 11, 2024Immatics Announces Pricing of $150 Million Public OfferingHouston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced t...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In

FAQ about Immatics

When was Immatics founded?

Immatics was founded in 2000.

How much funding has Immatics raised?

Immatics has raised $446.39M in total across 6 funding rounds.

What funding rounds has Immatics raised?

Parsers VC lists 6 funding rounds of Immatics, among them a funding round of $75M on Aug 28, 2019, a Series E round of $58M on Oct 4, 2017 and a Series D round of $45.99M on Jul 16, 2014.

Who has invested in Immatics?

Parsers VC lists 5 investors of Immatics, among them b2venture, Timefolio Capital and Wellington Partners.

What has the press written about Immatics?

Parsers VC has collected 67 articles mentioning Immatics, among them “Granite Bio: A New Force in Immunology with $100 Million Backing” (Apr 26, 2025) and “Granite Bio: Immunology Company Debuts With $100 Million In Funding” (Apr 25, 2025).

Is Immatics still active?

Yes, Immatics is active; its latest activity on Parsers VC dates from Aug 13, 2026.